Powered by

AgeneBio Announces First Patient Enrollment in the Phase 3 Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease

Jan 17, 2019 - PR Newswire

PR Newswire

AgeneBio announced today that it has enrolled its first patient in a Phase 3 clinical trial evaluating the efficacy of AGB101, a once-a-day investigational medication to treat amnestic Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD). The clinical trial, known as "HOPE4MCI" (http://www.hope4mci.org) will enroll 830 patients in the United States, Canada and Europe.

"We are very excited to have commenced the next phase of development on this novel approa...